UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )*

pSivida Limited

(Name of Issuer)

ordinary shares

(Title of Class of Securities)

74439M107 (ADS)

(CUSIP Number)

Margaret M. Foran

Senior Vice President - Corporate Governance,

Associate General Counsel & Secretary

Pfizer Inc.

235 East 42nd Street

New York, New York 10017

212-733-4802

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

July 13, 2007

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report

the acquisition that is the subject of this Schedule 13D, and is filing this

schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),

check the following box. |_|

CUSIP No. 74439M107 (ADS)

1. Names of Reporting Persons I.R.S. Identification Nos. of above persons (entities

only).

Pfizer Inc. 13-5315170

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only ........................................................................................

4. Source of Funds (See Instructions) ......WC..................................................

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d)

or 2(e)

6. Citizenship or Place of Organization Delaware, U.S.A.

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY EACH REPORTING

PERSON WITH

7. Sole Voting Power.. 74,483,748...........................

8. Shared Voting Power ............................................

9. Sole Dispositive Power 74,483,748 ........................

10. Shared Dispositive Power ..................................

11. Aggregate Amount Beneficially Owned by Each Reporting Person. 74,483,748.............

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11) 10.49%

14. Type of Reporting Person (See Instructions) CO

Item 1. Security and Issuer

Ordinary shares; pSivida Limited, Level 12 BGC Centre, 28 The Esplanade, Perth

WA 6000, Australia.

Item 2. Identity and Background

(a) Pfizer Inc.

(b) 235 East 42nd Street, New York, New York 10017

(c) pharmaceuticals

(d) No

(e) No

(f) Delaware, U.S.A.

Item 3. Source and Amount of Funds or Other Consideration

Working Capital. Pfizer Inc. had purchased 22,483,748 ordinary shares of pSivida

Limited (less than 5% of outstanding) on April 4, 2007 for $5,000,000.

Item 4. Purpose of Transaction

Pfizer acquired shares of pSivida Limited on April 4, 2007 and on July 13, 2007

as part of its obligation to pSivida in connection with a collaborative research

and licensing agreement entered into by the parties on April 3, 2007.

Item 5. Interest in Securities of the Issuer

(a) 74,483,748 ordinary shares; 10.49% of outstanding

(b) 74,483,748 shares

(c) none

(d) N.A.

(e) N.A.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect

to Securities of the Issuer

None

Item 7. Material to Be Filed as Exhibits

None

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify

that the information set forth in this statement is true, complete and correct.

July 16, 2007

Date

Signature /s/ Charles F. Raeburn

Charles F. Raeburn, Assistant General Counsel and Assistant Secretary, Pfizer

Inc.

Name/Title

Attention: Intentional misstatements or omissions of fact

Constitute Federal criminal violations (See 18 U.S.C. 1001)